Thomas Prebet, MD, PhD
Biography
Research & Publications
News
Locations
Appointments
Biography
After completing his doctorate in medical hematology and oncology in Lyon, France, Dr. Prebet joined Institut Paoli-Calmettes in Marseille, France and completed a fellowship in Johns Hopkins University (Baltimore, MA, USA) as a Fullbright alumni. Dr. Prebet is currently the director of the inpatient hematology unit and the medical director of the hematology division of Yale Clinical Trial Office. He is the associate director of the myeloid malignancies program in the hematology department of the Yale Cancer Center, New haven, CT. He is developing myeloid malignancies clinical trials and translational works for advanced phase acute myeloid leukemia and myelodysplastics syndromes. The current works gave the basis for defining demethylating agent failure outcome (Prebet JCO 2011, Hematologica 2012, British Journal of Hematology 2012, Blood Advance 2018), contributed to his knowledge of combinations therapies based on HDAC inhibitors (Prebet JCO 2014, Prebet Leuk Res 2014) and gave the first insights on the implication of Wnt non canonical pathway in acute myeloid leukemia (Prebet Blood 2011). Dr Prebet is the coordinating investigator of several clinical trials for myelodysplastic syndromes and acute leukemia patients and contributed to 110 peer reviewed manuscript.
Education & Training
- Post-Doctoral FellowJohns Hopkins University (2010)
- PhDCentre de Recherche en Cancerologie (2009)
- MSClaude Bernard University (2005)
- ResidentUniversity Hospitals of Lyon (2004)
- MDMontpellier University (2000)
Activities
- Management of Elderly AMLParis, Île-de-France, France 2019Management of Elderly AML
- ASH 2015 highlights in acute myeloid leukemiaOmaha, NE, United States 2016ASH 2015 highlights in acute myeloid leukemia
- Trends in clinical development in myelodysplastic syndromesHouston, TX, United States 2015Trends in clinical development in myelodysplastic syndromes
- Myelodysplastic syndromes: Challenges of secondTampa, FL, United States 2015Myelodysplastic syndromes: Challenges of second
- Supportive care for myelodysplastic syndromes in 2015 line treatmentsWashington, DC, United States 2015Supportive care for myelodysplastic syndromes in 2015 line treatments
- Outcome of patients treated for MDS after failure of lenalidomide therapyOrlando, FL, United States 2015Outcome of patients treated for MDS after failure of lenalidomide therapy
- Current treatment strategies in MDSMarseille, Provence-Alpes-Côte d'Azur, France 2014Current treatment strategies in MDS
- MDS: State of the art in 2014Marseille, Provence-Alpes-Côte d'Azur, France 2014MDS: State of the art in 2014
- High risk MDS: Clinical management after frontline treatment failureDresden, SN, Germany 2014High risk MDS: Clinical management after frontline treatment failure
- Chemo-genomic approaches in AMLParis, Île-de-France, France 2014Chemo-genomic approaches in AML
- Second line treatments in high risk MDSAvignon, Provence-Alpes-Côte d'Azur, France 2014Second line treatments in high risk MDS
- Elderly high risk MDS: treatment options and supportive care recommendationsAix-en-Provence, Provence-Alpes-Côte d'Azur, France 2013Elderly high risk MDS: treatment options and supportive care recommendations
- Ongoing and futures trials in myelodysplastic syndromesAix-en-Provence, Provence-Alpes-Côte d'Azur, France 2013Ongoing and futures trials in myelodysplastic syndromes
- AML 2013: State of the art” and “MDS 2013: state of the artMarseille, Provence-Alpes-Côte d'Azur, France 2013AML 2013: State of the art” and “MDS 2013: state of the art
- Investigational approaches in high risk MDS: second line treatmentsParis, Île-de-France, France 2013Investigational approaches in high risk MDS: second line treatments
- High risk MDS: second line optionsParis, Île-de-France, France 2013High risk MDS: second line options
- Cancer biomarkers and woman fertility preservationLyon, Auvergne-Rhône-Alpes, France 2012Cancer biomarkers and woman fertility preservation
- Implication of PTK7 receptor in AMLLondon, England, United Kingdom 2012Implication of PTK7 receptor in AML
- Outcome of MDS patients with hypomethylating agent failureDresden, SN, Germany 2012Outcome of MDS patients with hypomethylating agent failure
- Clinical trials in myelodysplastic syndromesAix-en-Provence, Provence-Alpes-Côte d'Azur, France 2011Clinical trials in myelodysplastic syndromes
- Hypomethylating agent failureHouston, TX, United States 2011Hypomethylating agent failure
- Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905Orlando, FL, United States 2010Prolonged Administration of Azacitidine with or without Entinostat Increases Rate of Hematologic Normalization for Myelodysplastic Syndrome and Acute Myeloid Leukemia with Myelodysplasia-Related Changes: Results of the US Leukemia Intergroup Trial E1905
- Outcome of patients treated for high risk MDS after azacitidine failureOrlando, FL, United States 2010Outcome of patients treated for high risk MDS after azacitidine failure
- Combination of gemtuzumab and high dose cytarabine for first relapse AMLParis, Île-de-France, France 2009Combination of gemtuzumab and high dose cytarabine for first relapse AML
- Core Binding Factor Acute Myeloid Leukemia of the Elderly Treated with Conventional Chemotherapy: A Collaborative Study of the French CBF AML IntergroupAtlanta, GA, United States 2008Core Binding Factor Acute Myeloid Leukemia of the Elderly Treated with Conventional Chemotherapy: A Collaborative Study of the French CBF AML Intergroup
Honors & Recognition
Award | Awarding Organization | Date |
---|---|---|
Award from association Laurette Fugain | Société Française d’hématologie | 2012 |
Award from French transfusion medicine society | association recherche transfusion/ société Française de Transfusion Sanguine | 2011 |
Professional Service
Organization | Role | Date |
---|---|---|
Inpatient Re-Organization Project Steering Committee | Member | 2019 - Present |
Inpatient Hospitalist Sub-Committee | Co-Chair | 2019 - Present |
Data and Safety Monitoring Board, Elderly French CLL Intergroup Study | Member | 2019 - Present |
Data and Safety Monitoring Board, French National AML Trial | Chair | 2019 - Present |
Data and Safety Monitoring Board, French National AML Trial | Member | 2018 - 2019 |
Smilow Telehealth Initiatives | Participant | 2018 - Present |
Yale Affiliated Hospital Program | Lecturer | 2018 - Present |
Yale Biological Safety Committee, Human Gene Therapy Subcommittee | Member | 2018 - Present |
Yale Cancer Center Chief Medical Officer Search Committee | Member | 2018 - Present |
Yale Cancer Center Clinical Trial Office Search Committee | Member | 2018 - Present |
Via Pathway Oncology | Co-Chair | 2018 - Present |
National Comprehensive Cancer Network | Committee Member | 2018 - Present |
National Cancer Center Network | AML committee | 2017 - Present |
Yale Cancer Center CROC Committee | Member | 2017 - Present |
Yale Cancer Center CAR-T Committee | Member | 2017 - Present |
Yale Cancer Center Process & Operations Committee | Member | 2017 - Present |
Yale-New Haven Hospital Duffy Service | Chairperson | 2017 - Present |
Yale Cancer Center Hematology Clinical Trial Office | Director | 2017 - Present |
Yale Cancer Center IRB Committee | Member | 2017 - Present |
Yale Human Research Protection Program | Human Investigation Committee | 2016 - Present |
Yale School of Medicine Hematology/Oncology Fellowship Program | Interviewer | 2016 - Present |
Yale School of Medicine Internal Medicine Residency Program | Interviewer | 2016 - Present |
Yale Human Research Protection Committee, HIC 1 | Member | 2016 - Present |
Onco hematology for French regional cancer grant program (PHRC regional) | Member | 2013 - 2015 |
Onco hematology for French regional cancer grant program (PHRC regional) | Scientific Advisor | 2013 - 2015 |
Onco Hematology for Fullbright commission (French American scholar exchange commission) | Member | 2011 - Present |
Onco Hematology for Fullbright commission (French American scholar exchange commission) | Scientific Advisor | 2011 - Present |
American Society of Hematology | Reviewer | 2010 - 2019 |
French NIH (AFFSAPS and ANSM) | Reviewer | 2009 - 2019 |
French regional cancer research agencies (CANCEROPOLE) for Paris, Lyon, and Marseille | Reviewer | 2009 - 2019 |
New England Journal of Medicine | Reviewer | 2009 - Present |
Blood | Reviewer | 2009 - Present |
Leukemia | Reviewer | 2009 - Present |
Cancer | Reviewer | 2009 - Present |
Drugs | Reviewer | 2009 - Present |
Hematologica | Reviewer | 2009 - Present |
Transfusion | Reviewer | 2009 - Present |
Epigenetics | Reviewer | 2009 - Present |
British Journal of Hematology | Reviewer | 2009 - Present |